相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan
Kuan-Yuan Chen et al.
ADVANCES IN THERAPY (2022)
Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial
Yi-Wen Huang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study
Yoko Edahiro et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2022)
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b
Jean-Jacques Kiladjian et al.
LEUKEMIA (2022)
Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis
Yi-Wen Huang et al.
VIRUSES-BASEL (2022)
SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia
Srdan Verstovsek et al.
FUTURE ONCOLOGY (2022)
A Phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C
Chi-Yi Chen et al.
JGH OPEN (2022)
Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C
Shih-Jer Hsu et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2021)
Real-world experience with Ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms
Cih-En Huang et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2021)
Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy
Hsien-Hong Lin et al.
JGH OPEN (2021)
Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival
Ghaith Abu-Zeinah et al.
LEUKEMIA (2021)
Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration
Narihisa Miyachi et al.
CLINICAL DRUG INVESTIGATION (2021)
Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects
Yi-Wen Huang et al.
ADVANCES IN THERAPY (2021)
Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study
Michael R. Grunwald et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
Heinz Gisslinger et al.
LANCET HAEMATOLOGY (2020)
Current management strategies for polycythemia vera and essential thrombocythemia
Paola Guglielmelli et al.
BLOOD REVIEWS (2020)
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B
Yi-Wen Huang et al.
HEPATOLOGY INTERNATIONAL (2020)
Updates in the management of polycythemia vera and essential thrombocythemia
Prithvirai Bose et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States
Ruben Mesa et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses
Tsewang Tashi et al.
LEUKEMIA (2018)
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
Tiziano Barbui et al.
BLOOD CANCER JOURNAL (2018)
Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo
Emmanuelle Verger et al.
BLOOD CANCER JOURNAL (2018)
Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera - Final Phase I/II Peginvera Study Results
Heinz Gisslinger et al.
BLOOD (2018)
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
Francesco Passamonti et al.
LANCET ONCOLOGY (2017)
Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)
Lucia Masarova et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2017)
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera
Heinz Gisslinger et al.
BLOOD (2015)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea
Matjaz Sever et al.
LEUKEMIA & LYMPHOMA (2014)
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
Giovanni Barosi et al.
BLOOD (2013)
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis
Richard T. Silver et al.
EXPERT REVIEW OF HEMATOLOGY (2013)
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
Jean-Jacques Kiladjian et al.
BLOOD (2008)
分享论文
